RDY Historical Income Statement
| RDY Stock | USD 74.55 0.53 0.72% |
Historical analysis of Dr Reddys income statement accounts such as Research Development of 23.4 B, Cost Of Revenue of 44.3 B, Income Before Tax of 73 B or Net Income Applicable To Common Shares of 54.4 B can show how well Dr Reddys Laboratories performed in making a profits. Evaluating Dr Reddys income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Dr Reddys's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Dr Reddys Laboratories latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Dr Reddys Laboratories is a good buy for the upcoming year.
RDY |
About RDY Income Statement Analysis
Dr Reddys Laboratories Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Dr Reddys shareholders. The income statement also shows RDY investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Dr Reddys Income Statement Chart
Dr Reddys Laboratories Income Statement is one of the three primary financial statements used for reporting RDY's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Dr Reddys Laboratories revenue and expense. Dr Reddys Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Dr Reddys' Other Operating Expenses is fairly stable compared to the past year. EBIT is likely to rise to about 116.3 B in 2024, whereas Cost Of Revenue is likely to drop slightly above 44.3 B in 2024. Add Fundamental
Total Revenue
Total revenue comprises all receipts Dr Reddys Laboratories generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Dr Reddys Laboratories minus its cost of goods sold. It is profit before Dr Reddys operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Operating Income
Operating Income is the amount of profit realized from Dr Reddys Laboratories operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Dr Reddys Laboratories is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Most accounts from Dr Reddys' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Dr Reddys Laboratories current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Dr Reddys Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. At this time, Dr Reddys' Other Operating Expenses is fairly stable compared to the past year. EBIT is likely to rise to about 116.3 B in 2024, whereas Cost Of Revenue is likely to drop slightly above 44.3 B in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 113.8B | 203.0B | 233.4B | 245.1B | Total Revenue | 214.4B | 245.9B | 282.8B | 296.9B |
Dr Reddys income statement Correlations
Click cells to compare fundamentals
Dr Reddys Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Dr Reddys income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 983M | 970M | 958M | 1.4B | 1.6B | 1.7B | |
| Total Revenue | 174.6B | 189.7B | 214.4B | 245.9B | 282.8B | 296.9B | |
| Gross Profit | 94.0B | 103.1B | 113.8B | 203.0B | 233.4B | 245.1B | |
| Operating Income | 37.1B | 36.1B | 40.8B | 96.3B | 110.7B | 116.3B | |
| Research Development | 15.4B | 16.5B | 17.5B | 19.4B | 22.3B | 23.4B | |
| Cost Of Revenue | 80.6B | 86.6B | 100.6B | 42.9B | 49.3B | 44.3B | |
| Income Before Tax | 18.0B | 28.3B | 32.3B | 60.5B | 69.6B | 73.0B | |
| Net Income Applicable To Common Shares | 19.5B | 19.1B | 23.6B | 45.1B | 51.8B | 54.4B | |
| Net Income | 19.5B | 17.2B | 23.6B | 45.1B | 51.8B | 54.4B | |
| Income Tax Expense | (1.5B) | 9.2B | 8.7B | 15.4B | 17.7B | 18.6B | |
| Depreciation And Amortization | 12.5B | 12.8B | 11.8B | 12.5B | 14.4B | 15.1B | |
| Selling General Administrative | 50.1B | 54.6B | 62.1B | 46.5B | 41.8B | 39.7B | |
| Other Operating Expenses | 141.8B | 156.8B | 177.4B | 160.5B | 184.6B | 193.8B | |
| Ebit | 37.1B | 36.1B | 40.8B | 96.3B | 110.7B | 116.3B | |
| Ebitda | 49.5B | 48.9B | 52.6B | 108.8B | 125.1B | 131.4B | |
| Total Operating Expenses | 61.2B | 70.1B | 76.8B | 117.6B | 135.3B | 142.0B | |
| Total Other Income Expense Net | (19.0B) | (7.7B) | (8.5B) | (35.8B) | (32.2B) | (30.6B) | |
| Net Income From Continuing Ops | 19.5B | 19.1B | 23.6B | 45.1B | 51.8B | 54.4B | |
| Tax Provision | (1.5B) | 9.2B | 8.7B | 15.4B | 17.7B | 18.6B | |
| Extraordinary Items | (3M) | 41M | 313M | 44M | 50.6M | 53.1M | |
| Interest Income | 2.0B | 1.7B | 3.1B | 1.1B | 952.2M | 1.5B | |
| Net Interest Income | (90M) | 1.7B | 2.1B | (1.4B) | (1.6B) | (1.6B) | |
| Reconciled Depreciation | 12.5B | 12.8B | 11.8B | 12.5B | 14.4B | 13.5B |
Currently Active Assets on Macroaxis
When determining whether Dr Reddys Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dr Reddys' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dr Reddys Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dr Reddys Laboratories Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Dr Reddys Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Dr Reddys Laboratories information on this page should be used as a complementary analysis to other Dr Reddys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Complementary Tools for RDY Stock analysis
When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |
Is Dr Reddys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dr Reddys. If investors know RDY will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dr Reddys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.103 | Dividend Share 40 | Earnings Share 3.76 | Revenue Per Share 272.4618 | Quarterly Revenue Growth 0.066 |
The market value of Dr Reddys Laboratories is measured differently than its book value, which is the value of RDY that is recorded on the company's balance sheet. Investors also form their own opinion of Dr Reddys' value that differs from its market value or its book value, called intrinsic value, which is Dr Reddys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dr Reddys' market value can be influenced by many factors that don't directly affect Dr Reddys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dr Reddys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dr Reddys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dr Reddys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.